Comparative Pharmacology
Head-to-head clinical analysis: ORPHENADRINE CITRATE versus ROLVEDON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORPHENADRINE CITRATE versus ROLVEDON.
ORPHENADRINE CITRATE vs ROLVEDON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic properties. Its exact mechanism of action is not fully understood, but it is believed to exert its effects by blocking muscarinic acetylcholine receptors and possibly by acting as an NMDA receptor antagonist. It may also have local anesthetic and antihistaminic properties.
ROLVEDON (eflapegrastim) is a long-acting granulocyte colony-stimulating factor (G-CSF) agonist. It binds to G-CSF receptors on neutrophil progenitors, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
100 mg orally twice daily. Maximum: 250 mg/day.
5 mg subcutaneously once weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 14 hours (range 11–20 hours) in adults; may be prolonged in elderly or hepatic impairment.
Approximately 20 hours in adults; prolonged in renal impairment, requiring dose adjustment
Primarily renal excretion of metabolites; less than 10% excreted unchanged. Also undergoes biliary excretion with fecal elimination of conjugates.
Primarily renal; approximately 80% of the dose excreted unchanged in urine, with minor biliary/fecal elimination (<10%)
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant